Our vision is to be The retina company and to be recognized as a leading global provider of devices and solutions to eyecare professionals.
We will help our customers improve patient care by providing innovative integrated products that deliver comprehensive disease diagnostics
and management solutions.
This year marks the 10-year anniversary of the FDA approval of selective laser trabeculoplasty, or SLT, in the treatment of open-angle glaucoma. The technology was developed and first introduced to the market by Lumenis® Ltd. in 1999. This article presents some of the unique aspects of SLT, along with observations from years of experience from the world’s leading experts in the procedure.
Over the years ISOPT has assembled an esteemed faculty of over 150 lecturers representing the major fields in ophthalmology. ISOPT faculty will examine the novelties and the current modes of ophthalmic therapeutic interventions. In addition, ISOPT is...
